FierceBiotech November 25, 2025

<a href="https://www.fiercebiotech.com/biotech/versants-dayra-dawns-50m-biogen-pact-oral-macrocyclic-peptide-mission" hreflang="en">Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission</a>

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen.